UA138772U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase genes (MTHFR C677T), nitric oxide synthase (eNOS T786C), endothelin, glycosaminoglycans (GAG), C-reactive protein (CKP), intern. With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, GAG> 28 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology, and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV) is determined in the patient's blood serum

Сб677тТ), nitric oxide synthase (6ЕеМО5 17860), content of endothelin, glycosaminoglycans (GAG), C-reactive protein (SRP), interleukin 6 (IL-6). With homozygous carriers of 677-TT, 786-SS, endothelin levels of 210 ng/ml, GAG »28 μmol/l, SRP »6 mg/l, IL-6 210 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are performed, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, GAG, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-TT, 786-SS, endothelin levels »10 ng/ml, GAG 228 μmol/l, SRP 26 mg/l, IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method

Patient K., 63 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. X-rays were examined and performed. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and eMmo5 17860 genes was determined in blood serum. The content of endothelin, HAG, SRP, and IL-6 was determined by immunoenzymatic method. Established homozygous carrier 677-

TT and 786-SS, endothelin levels - 24 ng/ml, GAG - 45 μmol/l, SRP - 15 mg/l, IL-b - 20 ng/l.

The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (ЕМО5 1786С), the content of endothelin, glycosaminoglycans (GAG), C-reactive protein (SRP), interleukin 6 (IL-6) and with homozygous carrier 677-TT, 786-SS and endothelin levels 210 ng/ml, GAG 228 μmol/l, SRP 26 mg/l, IL-6 »10 ng/l predict the development of osteoarthritis.